Fierce Pharma

SEPTEMBER 14, 2024

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative breast cancer (TNBC). | In 2021, the FDA blasted Merck for using premature data to pursue a Keytruda approval in early-stage triple-negative breast cancer. Now, the PD-1 inhibitor has gold-standard overall survival data to back its case.

FDA 245

FDA 245

Cesare Ferrari

SEPTEMBER 14, 2024

If you’re one of those asking what skills a medical sales rep will need to have to successfully navigate the complexity in today’s highly competitive medical market , you’ve arrived at the answer. We can all agree that gone are the days when a sales rep required simple interpersonal, communication, and closing skills. Clearly, the competitiveness of the medical market demands more of a sales rep.

Medical sales reps 52

Medical sales reps Medical sales Sales Medical 52

Fierce Pharma

SEPTEMBER 14, 2024

AstraZeneca’s Imfinzi recently became the first PD-1/L1 inhibitor to deliver a patient survival win in muscle-invasive bladder cancer (MIBC). | AstraZeneca’s detailed data show exactly how Imfinzi became the first PD-1/L1 inhibitor to deliver a patient survival win in muscle-invasive bladder cancer. But the win came from a perioperative regimen, a trial design that’s been criticized by the FDA in lung cancer.

FDA 185

FDA Patients 185

Pharmacy Times

SEPTEMBER 14, 2024

An ESMO 2024 presentation explores the growing role of the gut microbiome in immunotherapy response, emerging diagnostic tools such as PCR chips, and innovative therapies such as fecal microbiota transplantation and microbiome-preserving strategies to improve patient outcomes.

Patients 59

Patients 59

Advertisement

Pharmacy Times

SEPTEMBER 14, 2024

Not only do diverse clinical cohorts improve the strength of the data, but it improves public trust in clinicians and the medical system as a whole.

Medical 55

Medical 55

Pharmacy Times

SEPTEMBER 14, 2024

The gut and intratumoral microbiota influence cancer development, progression, and treatment responses, highlighting the potential for treatment strategies that leverage these microbial interactions to enhance cancer therapies.

26

26